Ormed Insulin Pills

It's Oramed. Whilst an interesting development, they themselves say that the main goal is to improve compliance (I.e. to make insulin therapy less scary in order to get more patients on insulin earlier)

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.



Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.